Kindstar Globalgene Technology Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 1/6
Kindstar Globalgene Technology has been growing earnings at an average annual rate of 64.8%, while the Healthcare industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 2% per year. Kindstar Globalgene Technology's return on equity is 0.1%, and it has net margins of 1%.
Wichtige Informationen
64.8%
Wachstumsrate der Gewinne
77.8%
EPS-Wachstumsrate
| Healthcare Wachstum der Industrie | 11.3% |
| Wachstumsrate der Einnahmen | 2.0% |
| Eigenkapitalrendite | 0.1% |
| Netto-Marge | 1.0% |
| Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Kindstar Globalgene Technology's (HKG:9960) Shareholders Have More To Worry About Than Only Soft Earnings
Oct 04
We Think That There Are More Issues For Kindstar Globalgene Technology (HKG:9960) Than Just Sluggish Earnings
Apr 03Recent updates
Kindstar Globalgene Technology's (HKG:9960) Shareholders Have More To Worry About Than Only Soft Earnings
Oct 04Kindstar Globalgene Technology, Inc.'s (HKG:9960) Shares Leap 29% Yet They're Still Not Telling The Full Story
Oct 03We Think That There Are More Issues For Kindstar Globalgene Technology (HKG:9960) Than Just Sluggish Earnings
Apr 03Kindstar Globalgene Technology (HKG:9960) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Aug 22Analysts Just Made A Notable Upgrade To Their Kindstar Globalgene Technology, Inc. (HKG:9960) Forecasts
Aug 18We're Not Very Worried About Kindstar Globalgene Technology's (HKG:9960) Cash Burn Rate
Jul 07Kindstar Global (Beijing) Technology, Inc. (HKG:9960) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 28Aufschlüsselung der Einnahmen und Ausgaben
Wie Kindstar Globalgene Technology Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 948 | 9 | 399 | 101 |
| 31 Mar 24 | 958 | 25 | 406 | 103 |
| 31 Dec 23 | 967 | 41 | 413 | 105 |
| 30 Sep 23 | 1,094 | 49 | 429 | 107 |
| 30 Jun 23 | 1,220 | 57 | 445 | 109 |
| 31 Mar 23 | 1,303 | 66 | 443 | 105 |
| 31 Dec 22 | 1,387 | 75 | 441 | 101 |
| 30 Sep 22 | 1,269 | 93 | 416 | 97 |
| 30 Jun 22 | 1,152 | 110 | 392 | 93 |
| 31 Mar 22 | 1,041 | -672 | 372 | 92 |
| 31 Dec 21 | 931 | -1,454 | 352 | 90 |
| 30 Sep 21 | 915 | -1,919 | 341 | 88 |
| 30 Jun 21 | 900 | -2,384 | 331 | 86 |
| 31 Mar 21 | 896 | -1,679 | 316 | 81 |
| 31 Dec 20 | 891 | -974 | 301 | 75 |
| 31 Dec 19 | 833 | -170 | 323 | 79 |
| 31 Dec 18 | 706 | -53 | 291 | 74 |
Qualität der Erträge: 9960 has a high level of non-cash earnings.
Wachsende Gewinnspanne: 9960's current net profit margins (1%) are lower than last year (4.7%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 9960 has become profitable over the past 5 years, growing earnings by 64.8% per year.
Beschleunigtes Wachstum: 9960's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Erträge im Vergleich zur Industrie: 9960 had negative earnings growth (-83.8%) over the past year, making it difficult to compare to the Healthcare industry average (-16.9%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 9960's Return on Equity (0.1%) is considered low.